{"Title": ["2 Best Biotech Stocks to Buy Right Now", "Nasdaq 100 Movers: ATVI, PYPL", "BioMarin, DiNAQOR To Develop Gene Therapies For Rare Genetic Cardiomyopathies", "Biomarin Pharma Q1 20 Earnings Conference Call At 4:15 PM ET", "BioMarin Blows Past Q1 Estimates, Projects 1st Year of Profitability in 2020", "Biomarin Pharmaceutical Inc (BMRN) Q1 2020 Earnings Call Transcript", "EARNINGS SUMMARY: Details of Biomarin Pharmaceutical Inc. Q1 Earnings Report", "Biomarin Pharmaceutical Q1 20 Earnings Conference Call At 4:15 PM ET", "2 Best Biotech Stocks to Buy Right Now", "Is BioMarin Pharmaceuticals Stock a Buy?", "Notable Two Hundred Day Moving Average Cross - BMRN", "30 Top Stocks and Funds to Beat the COVID-19 Bear Market", "3 Top Biotech Stocks to Buy Now", "Implied VUG Analyst Target Price: $203", "Why BioMarin Pharmaceutical, Bristol-Myers Squibb, and bluebird bio Are Getting Hammered Monday", "Why These Drug Stocks Soared Today", "Look Under The Hood: QQXT Has 10% Upside", "Here's Why Emergent Biosolutions, BioMarin, and Nuvasive Fell on Monday", "Biomarin Pharmaceutical Inc (BMRN) Q4 2019 Earnings Call Transcript", "BioMarin Expects To Be Profitable In FY20; Revenue To Rise 14%-20%", "Biomarin Pharmaceutical Inc. Q4 adjusted earnings of -$ per share", "Biomarin Pharma Q4 19 Earnings Conference Call At 4:30 PM ET", "First Week of October 16th Options Trading For BioMarin Pharmaceutical (BMRN)", "BioMarin's Novel Treatment Promises to Disrupt Competitors", "Why BioMarin Pharmaceutical Inc. Stock Is Fading Today", "Nasdaq 100 Movers: ALGN, BMRN", "FDA Gives BioMarin Pharmaceuticals' Hemophilia Gene Therapy Priority Review", "Why Invitae's Q4 Results Failed to Wow Investors", "Codexis Is Chasing a Blockbuster Opportunity. Can It Compete With Gene Therapies?", "Interesting BMRN Put And Call Options For March 20th", "Add Up The Parts: FBT Could Be Worth $182", "3 Top Biotech Picks for 2020", "Noteworthy Friday Option Activity: GLUU, BMRN, SEAS", "BioMarin Considers $3 Million Price Tag for New Hemophilia Gene Therapy", "3 Healthcare Stocks That Are Coming Back to Life", "Biomarin Pharma To Present At J.P. Morgan Conference; Webcast At 10:30 AM ET", "These 3 Biotech Stocks Could Be Top Stocks in 2020", "Notable Thursday Option Activity: FGEN, BMRN, ESTC", "3 Best Stocks for 2020: The Race Is On", "Analysts See 11% Upside For The Holdings of BBH", "Notable Friday Option Activity: DOCU, BMRN, BHVN", "BioMarin: Vosoritide Phase 3 Study Shows Positive Results - Quick Facts", "Are These Biotech Companies Buyout Candidates? Deal Or No Deal?", "Why Has Alnylam's Stock Gained 25% In The Last Two Weeks", "Why Has Alnylam's Stock Gained 25% In The Last Two Weeks", "Why Has Alnylam's Stock Gained 25% In The Last Two Weeks", "Here's Why BioMarin Pharmaceutical Leapt 10.2% in November", "Better Buy: Editas Medicine or Sangamo Therapeutics?", "AXSM Again Proves It Is Awesome, MIRM Leaps To $22, WVE Doesn't Go The Distance", "Implied QQXT Analyst Target Price: $62"], "Elapsed Time": ["3 DAYS AGO", "MAY 7, 2020", "MAY 3, 2020", "APR 30, 2020", "APR 30, 2020", "APR 30, 2020", "APR 29, 2020", "APR 29, 2020", "3 DAYS AGO", "APR 8, 2020", "APR 7, 2020", "APR 5, 2020", "APR 2, 2020", "MAR 26, 2020", "MAR 16, 2020", "MAR 13, 2020", "APR 27, 2020", "MAR 9, 2020", "FEB 27, 2020", "FEB 26, 2020", "FEB 26, 2020", "FEB 26, 2020", "FEB 26, 2020", "FEB 26, 2020", "MAR 12, 2020", "FEB 21, 2020", "FEB 20, 2020", "FEB 20, 2020", "JAN 28, 2020", "JAN 22, 2020", "JAN 21, 2020", "JAN 20, 2020", "FEB 21, 2020", "JAN 16, 2020", "JAN 15, 2020", "JAN 13, 2020", "JAN 11, 2020", "JAN 9, 2020", "JAN 6, 2020", "DEC 20, 2019", "JAN 17, 2020", "DEC 16, 2019", "DEC 14, 2019", "DEC 5, 2019", "DEC 5, 2019", "DEC 5, 2019", "DEC 4, 2019", "NOV 26, 2019", "DEC 16, 2019", "NOV 18, 2019"], "Published Date": ["Jun 1, 2020 10:35AM EDT", "May 7, 2020 10:25AM EDT", "May 3, 2020 10:42PM EDT", "Apr 30, 2020 3:00PM EDT", "Apr 30, 2020 6:54AM EDT", "Apr 30, 2020 2:31AM EDT", "Apr 29, 2020 4:05PM EDT", "Apr 29, 2020 3:00PM EDT", "Jun 1, 2020 10:35AM EDT", "Apr 8, 2020 7:36AM EDT", "Apr 7, 2020 5:15PM EDT", "Apr 5, 2020 5:00PM EDT", "Apr 2, 2020 6:32AM EDT", "Mar 26, 2020 7:51AM EDT", "Mar 16, 2020 1:41PM EDT", "Mar 13, 2020 5:38PM EDT", "Apr 27, 2020 8:45AM EDT", "Mar 9, 2020 9:36PM EDT", "Feb 27, 2020 3:00AM EST", "Feb 26, 2020 5:19PM EST", "Feb 26, 2020 4:10PM EST", "Feb 26, 2020 3:01PM EST", "Feb 26, 2020 11:24AM EST", "Feb 26, 2020 7:08AM EST", "Mar 12, 2020 11:47AM EDT", "Feb 21, 2020 10:22AM EST", "Feb 20, 2020 7:05PM EST", "Feb 20, 2020 7:00AM EST", "Jan 28, 2020 10:58AM EST", "Jan 22, 2020 11:35AM EST", "Jan 21, 2020 4:01PM EST", "Jan 20, 2020 1:20PM EST", "Feb 21, 2020 3:26PM EST", "Jan 16, 2020 4:58PM EST", "Jan 15, 2020 10:02AM EST", "Jan 13, 2020 9:32AM EST", "Jan 11, 2020 8:01AM EST", "Jan 9, 2020 3:18PM EST", "Jan 6, 2020 11:35AM EST", "Dec 20, 2019 8:48AM EST", "Jan 17, 2020 3:19PM EST", "Dec 16, 2019 8:36AM EST", "Dec 14, 2019 3:14AM EST", "Dec 5, 2019 12:30AM EST", "Dec 5, 2019 12:30AM EST", "Dec 5, 2019 12:30AM EST", "Dec 4, 2019 1:21AM EST", "Nov 26, 2019 7:00AM EST", "Dec 16, 2019 9:49PM EST", "Nov 18, 2019 7:47AM EST"], "Link": ["https://www.nasdaq.com/articles/2-best-biotech-stocks-to-buy-right-now-2020-06-01", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-atvi-pypl-2020-05-07", "https://www.nasdaq.com/articles/biomarin-dinaqor-to-develop-gene-therapies-for-rare-genetic-cardiomyopathies-2020-05-03", "https://www.nasdaq.com/articles/biomarin-pharma-q1-20-earnings-conference-call-at-4%3A15-pm-et-2020-04-30", "https://www.nasdaq.com/articles/biomarin-blows-past-q1-estimates-projects-1st-year-of-profitability-in-2020-2020-04-30", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-inc-bmrn-q1-2020-earnings-call-transcript-2020-04-30", "https://www.nasdaq.com/articles/earnings-summary%3A-details-of-biomarin-pharmaceutical-inc.-q1-earnings-report-2020-04-29", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-q1-20-earnings-conference-call-at-4%3A15-pm-et-2020-04-29", "https://www.nasdaq.com/articles/2-best-biotech-stocks-to-buy-right-now-2020-06-01", "https://www.nasdaq.com/articles/is-biomarin-pharmaceuticals-stock-a-buy-2020-04-08", "https://www.nasdaq.com/articles/notable-two-hundred-day-moving-average-cross-bmrn-2020-04-07", "https://www.nasdaq.com/articles/30-top-stocks-and-funds-to-beat-the-covid-19-bear-market-2020-04-05", "https://www.nasdaq.com/articles/3-top-biotech-stocks-to-buy-now-2020-04-02", "https://www.nasdaq.com/articles/implied-vug-analyst-target-price%3A-%24203-2020-03-26", "https://www.nasdaq.com/articles/why-biomarin-pharmaceutical-bristol-myers-squibb-and-bluebird-bio-are-getting-hammered", "https://www.nasdaq.com/articles/why-these-drug-stocks-soared-today-2020-03-13", "https://www.nasdaq.com/articles/look-under-the-hood%3A-qqxt-has-10-upside-2020-04-27", "https://www.nasdaq.com/articles/heres-why-emergent-biosolutions-biomarin-and-nuvasive-fell-on-monday-2020-03-10", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-inc-bmrn-q4-2019-earnings-call-transcript-2020-02-27", "https://www.nasdaq.com/articles/biomarin-expects-to-be-profitable-in-fy20-revenue-to-rise-14-20-2020-02-26", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-inc.-q4-adjusted-earnings-of-%24-per-share-2020-02-26", "https://www.nasdaq.com/articles/biomarin-pharma-q4-19-earnings-conference-call-at-4%3A30-pm-et-2020-02-26", "https://www.nasdaq.com/articles/first-week-of-october-16th-options-trading-for-biomarin-pharmaceutical-bmrn-2020-02-26", "https://www.nasdaq.com/articles/biomarins-novel-treatment-promises-to-disrupt-competitors-2020-02-26", "https://www.nasdaq.com/articles/why-biomarin-pharmaceutical-inc.-stock-is-fading-today-2020-03-12", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-algn-bmrn-2020-02-21", "https://www.nasdaq.com/articles/fda-gives-biomarin-pharmaceuticals-hemophilia-gene-therapy-priority-review-2020-02-21", "https://www.nasdaq.com/articles/why-invitaes-q4-results-failed-to-wow-investors-2020-02-20", "https://www.nasdaq.com/articles/codexis-is-chasing-a-blockbuster-opportunity.-can-it-compete-with-gene-therapies-2020-01", "https://www.nasdaq.com/articles/interesting-bmrn-put-and-call-options-for-march-20th-2020-01-22", "https://www.nasdaq.com/articles/add-up-the-parts%3A-fbt-could-be-worth-%24182-2020-01-21", "https://www.nasdaq.com/articles/3-top-biotech-picks-for-2020-2020-01-20", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity%3A-gluu-bmrn-seas-2020-02-21", "https://www.nasdaq.com/articles/biomarin-considers-%243-million-price-tag-for-new-hemophilia-gene-therapy-2020-01-16", "https://www.nasdaq.com/articles/3-healthcare-stocks-that-are-coming-back-to-life-2020-01-15", "https://www.nasdaq.com/articles/biomarin-pharma-to-present-at-j.p.-morgan-conference-webcast-at-10%3A30-am-et-2020-01-13", "https://www.nasdaq.com/articles/these-3-biotech-stocks-could-be-top-stocks-in-2020-2020-01-11", "https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-fgen-bmrn-estc-2020-01-09", "https://www.nasdaq.com/articles/3-best-stocks-for-2020%3A-the-race-is-on-2020-01-06", "https://www.nasdaq.com/articles/analysts-see-11-upside-for-the-holdings-of-bbh-2019-12-20", "https://www.nasdaq.com/articles/notable-friday-option-activity%3A-docu-bmrn-bhvn-2020-01-17", "https://www.nasdaq.com/articles/biomarin%3A-vosoritide-phase-3-study-shows-positive-results-quick-facts-2019-12-16", "https://www.nasdaq.com/articles/are-these-biotech-companies-buyout-candidates-deal-or-no-deal-2019-12-14", "https://www.nasdaq.com/articles/why-has-alnylams-stock-gained-25-in-the-last-two-weeks-2019-12-05-0", "https://www.nasdaq.com/articles/why-has-alnylams-stock-gained-25-in-the-last-two-weeks-2019-12-05-1", "https://www.nasdaq.com/articles/why-has-alnylams-stock-gained-25-in-the-last-two-weeks-2019-12-05", "https://www.nasdaq.com/articles/heres-why-biomarin-pharmaceutical-leapt-10.2-in-november-2019-12-04", "https://www.nasdaq.com/articles/better-buy%3A-editas-medicine-or-sangamo-therapeutics-2019-11-26", "https://www.nasdaq.com/articles/axsm-again-proves-it-is-awesome-mirm-leaps-to-%2422-wve-doesnt-go-the-distance-2019-12-16", "https://www.nasdaq.com/articles/implied-qqxt-analyst-target-price%3A-%2462-2019-11-18"], "Content": ["When it comes to biotech stocks, the recent focus has been on companies working on coronavirus treatments or prevention. While it's fine to jump on that bandwagon, there are other biotech investment opportunities that may not double in value overnight but will surely bear fruit in the long term.I'm thinking of Vertex Pharmaceuticals (NASDAQ: VRTX) and BioMarin Pharmaceutical (NASDAQ: BMRN). Shares of both companies fell as the market crashed but have proved their resilience in the following weeks. Vertex and BioMarin\u00a0now are up 30% and 25%, respectively, this year. Meanwhile, the S&P 500 is down 5.7%.\u00a0Here's why these two stocks are a buy right now.END", "In early trading on Thursday, shares of PayPal Holdings topped the list of the day's best performing components of the Nasdaq 100 index, trading up 11.9%.  Year to date, PayPal Holdings registers a 32.7% gain.\n\nAnd the worst performing Nasdaq 100 component thus far on the day is Activision Blizzard, trading down 2.1%.  Activision Blizzard is showing a gain of 20.0% looking at the year to date performance.\n\nTwo other components making moves today are BioMarin Pharmaceutical, trading down 1.7%, and DexCom, trading up 8.9% on the day.\n\n \n\n\n\n\n\n\n\nVIDEO: Nasdaq 100 Movers: ATVI, PYPL\nEND", "(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN) said Sunday that it has reached a preclinical collaboration and license agreement with DiNAQOR AG to develop novel gene therapies to treat rare genetic cardiomyopathies. The company did not disclose financial terms.DiNAQOR will receive an undisclosed upfront payment and is eligible to receive development, regulatory and commercial milestones on product sales in addition to tiered royalties on worldwide sales. BioMarin reiterated its 2020 GAAP net income guidance of $20 million to $80 million, inclusive of the collaboration.The license initially covers DiNAQOR's lead program, DiNA-001 for MYBPC3 hypertrophic cardiomyopathy. Hypertrophic cardiomyopathy is one of the most common genetic heart diseases.END", "(RTTNews) - Biomarin Pharmaceutical Inc. (BMRN) will host a conference call at 4:15 PM ET on April 30, 2020, to discuss Q1 20 earnings results.To access the live webcast, log on to www.biomarin.comTo listen to the call, dial (833) 360-0852 (US) or (630) 652-5841 (International), Conference ID: 6194595.For a replay call, dial (855) 859-2056 (US) or (404) 537-3406 (International), Conference ID: 6194595. END", "Investors looking for something of a safe haven in the COVID-19 storm might like\u00a0BioMarin Pharmaceutical\u00a0(NASDAQ: BMRN). While most stocks have languished in 2020, the biotech's shares are up 12% so far this year.BioMarin could pick up even more momentum now. The company announced its first-quarter results after the market closed on Wednesday. Here are the highlights from BioMarin's Q1 update.END", "END", "(RTTNews) - Below are the earnings highlights for Biomarin Pharmaceutical Inc. (BMRN):-Earnings: $81.38 million in Q1 vs. -$56.47 million in the same period last year. \n-EPS: $0.44 in Q1 vs. -$0.32 in the same period last year. \n-Analysts projected $0.05\t per share \n-Revenue: $502.07 million in Q1 vs. $400.75 million in the same period last year. -Guidance:\nFull year revenue guidance: $1,850 - $1,950 Mln\n The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.END", "(RTTNews) - Biomarin Pharmaceutical Inc. (BMRN) will host a conference call at 4:15 PM ET on April 29, 2019, to discuss Q1 20 earnings results.To access the live webcast, log on to www.biomarin.comTo listen to the call, dial (833) 360-0852 (US) or (833) 360-0852 (International), Conference ID: 6194595.For a replay call, dial (855) 859-2056 (US) or (404) 537-3406 (International), Conference ID: 6194595. END", "When it comes to biotech stocks, the recent focus has been on companies working on coronavirus treatments or prevention. While it's fine to jump on that bandwagon, there are other biotech investment opportunities that may not double in value overnight but will surely bear fruit in the long term.I'm thinking of Vertex Pharmaceuticals (NASDAQ: VRTX) and BioMarin Pharmaceutical (NASDAQ: BMRN). Shares of both companies fell as the market crashed but have proved their resilience in the following weeks. Vertex and BioMarin\u00a0now are up 30% and 25%, respectively, this year. Meanwhile, the S&P 500 is down 5.7%.\u00a0Here's why these two stocks are a buy right now.END", "BioMarin Pharmaceuticals (NASDAQ: BMRN)\u00a0has not escaped the market sell-off caused by the COVID-19 pandemic. The stock dropped 21% from its high of $97.10, set March 4, before quickly rebounding; year to date, the biopharma's shares are down 5%. BioMarin is trading at 59.2 times future earnings, and the company's forward price-to-earnings-growth (PEG) ratio is 0.76. Given these valuation metrics, should investors consider buying shares?\u00a0END", "In trading on Tuesday, shares of BioMarin Pharmaceutical Inc (Symbol: BMRN) crossed below their 200 day moving average of $79.76, changing hands as low as $79.14 per share.  BioMarin Pharmaceutical Inc shares are currently trading down about 3.5% on the day.  The chart below shows the one year performance of BMRN shares, versus its 200 day moving average:\n\n   END", "With the Dow Jones Industrial Average, the\u00a0Nasdaq Composite Index, and the\u00a0S&P 500 all down by more than 20% from their recent highs, there's no doubt that the COVID-19 pandemic has pushed U.S. stock markets into bear territory. What's more, the social distancing measures being used to control the spread of the SARS-CoV-2 virus have badly damaged the global economy and global supply chains and have put a number of industries, such as airlines, brick-and-mortar retailers, and sit-down restaurants, in a serious financial bind.\u00a0The good news is that this pandemic will eventually end. Several pharmaceutical companies are trialing a variety of novel therapeutics that could shorten the clinical course of the disease and perhaps lessen its severity in acute cases, leading to fewer fatalities. Moreover, numerous vaccine candidates are under development, some of which could be available for widespread use as soon as mid-2021.END", "For stock investors, there really hasn't been anywhere to hide from the market debacle that's followed from the COVID-19 pandemic. All industries have been hit as investors dump risky assets.It isn't too surprising that shares of biotechnology companies have fallen along with the rest, since they typically involve significant risk. On the other hand, the pandemic is drawing attention to the enormous strides the industry has made in developing new platforms for vaccines and therapeutics. We may be seeing the political threat that worried investors so much in 2019 dissolve before our very eyes as the world looks to some of these companies for help in the global crisis.It isn't necessary to make risky and speculative bets to profit from biotech stocks in today's environment. Vertex Pharmaceuticals (NASDAQ: VRTX), Emergent BioSolutions (NYSE: EBS), and BioMarin Pharmaceutical\u00a0(NASDAQ: BMRN) all have healthy and profitable growth, and are reasonably priced.END", "Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. \tFor the Vanguard Growth ETF (Symbol: VUG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $202.97 per unit.\n\n\nWith VUG trading at a recent price near $151.14 per unit, that means that analysts see 34.29% upside for this ETF looking through to the average analyst targets of the underlying holdings.   Three of VUG's underlying holdings with notable upside to their analyst target prices are Newell Brands Inc (Symbol: NWL), BioMarin Pharmaceutical Inc (Symbol: BMRN), and Broadcom Inc (Symbol: AVGO). Although NWL has traded at a recent price of $12.76/share, the average analyst target is 48.90% higher at $19.00/share. Similarly, BMRN has 46.22% upside from the recent share price of $80.47 if the average analyst target price of $117.67/share is reached, and analysts on average are expecting AVGO to reach a target price of $310.64/share, which is 42.79% above the recent price of $217.55. Below is a twelve month price history chart comparing the stock performance of NWL, BMRN, and AVGO:  \n\n END", "END", "END", "Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. \tFor the First Trust NASDAQ-100 Ex-Technology Sector Index Fund ETF (Symbol: QQXT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $60.33 per unit.\n\n\nWith QQXT trading at a recent price near $55.04 per unit, that means that analysts see 9.62% upside for this ETF looking through to the average analyst targets of the underlying holdings.   Three of QQXT's underlying holdings with notable upside to their analyst target prices are Trip.com Group Ltd (Symbol: TCOM), Sirius XM Holdings Inc (Symbol: SIRI), and BioMarin Pharmaceutical Inc (Symbol: BMRN). Although TCOM has traded at a recent price of $23.78/share, the average analyst target is 48.48% higher at $35.31/share. Similarly, SIRI has 28.39% upside from the recent share price of $5.50 if the average analyst target price of $7.07/share is reached, and analysts on average are expecting BMRN to reach a target price of $117.67/share, which is 20.92% above the recent price of $97.31. Below is a twelve month price history chart comparing the stock performance of TCOM, SIRI, and BMRN:  \n\n END", "END", "END", "(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN) said, for fiscal 2020, the company projects GAAP net income in a range of $20 million to $80 million; non-GAAP income of $260 million to $310 million; and total revenues of $1.95 billion to $2.05 billion. Palynziq net product revenues are projected between $180 million to $210 million, a significant growth over 2019. Fourth-quarter non-GAAP income was $46.4 million, compared to a loss of $10.9 million, a year ago. Total net product revenues increased to $436.6 million, from $347.2 million, prior year. Palynziq net product revenues increased by $23.6 million, driven by a combination of revenue from patients achieving maintenance dosing and new patients initiating therapy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.END", "(RTTNews) - Below are the earnings highlights for Biomarin Pharmaceutical Inc. (BMRN):-Earnings: $15.0 million in Q4 vs. -$3.7 million in the same period last year. \n-EPS: $0.08 in Q4 vs. -$0.03 in the same period last year. \n-Revenue: $454.4 million in Q4 vs. $353.2 million in the same period last year.\n The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.END", "(RTTNews) - Biomarin Pharmaceutical Inc. (BMRN) will host a conference call at 4:30 PM ET on February 26, 2020, to discuss Q4 19 earnings results.To access the live webcast, log on to www.biomarin.comTo listen to the call, dial (866) 502-9859 (US) or (574) 990-1362 (International), Conference ID: 9967337.For a replay call, dial (855) 859-2056 (US) or (404) 537-3406 (International), Conference ID: 9967337. END", "Investors in BioMarin Pharmaceutical Inc. (Symbol: BMRN) saw new options begin trading this week, for the October 16th expiration.  One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.   At Stock Options Channel, our YieldBoost formula has looked up and down the BMRN options chain for the new October 16th contracts and identified one put and one call contract of particular interest.The put contract at the $90.00 strike price has a current bid of $9.60.  If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $90.00, but will also collect the premium, putting the cost basis of the shares at $80.40 (before broker commissions).  To an investor already interested in purchasing shares of BMRN, that could represent an attractive alternative to paying $91.08/share today.\n\nBecause the $90.00 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless.  The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 58%.  Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract.  Should the contract expire worthless, the premium would represent a 10.67% return on the cash commitment, or 16.71% annualized \u2014 at Stock Options Channel we call this the YieldBoost.\n\n\nBelow is a chart showing the trailing twelve month trading history for BioMarin Pharmaceutical Inc., and highlighting in green where the $90.00 strike is located relative to that history:\n\nEND", "Gene therapy maker BioMarin Pharmaceuticals (NASDAQ: BMRN) has seen impressive growth recently, with the stock up more than 46% since October.\u00a0The 22-year-old company focuses on developing innovative therapies for rare genetic diseases, addressing conditions such as hemophilia, phenylketonuria (PKU), and a few others affecting children.\u00a0Most recently, BioMarin has been working on a novel therapy that promises to give its competitors, such as Roche (OTC: RHHBY) and Sangamo Therapeutics\u00a0(NASDAQ: SGMO), a run for their money\u00a0in this space. A recent update on BioMarin's manufacturing plans indicates that the company plans to leave no room for its competitors to grow.\u00a0END", "END", "\nIn early trading on Friday, shares of BioMarin Pharmaceutical topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.3%.  Year to date, BioMarin Pharmaceutical registers a 9.5% gain.\n\nAnd the worst performing Nasdaq 100 component thus far on the day is Align Technology, trading down 4.8%.  Align Technology is lower by about 7.1% looking at the year to date performance.\n\nTwo other components making moves today are Advanced Micro Devices, trading down 3.8%, and Gilead Sciences, trading up 1.2% on the day.\n\n \n\n\n\n\n\n\n\nVIDEO: Nasdaq 100 Movers: ALGN, BMRN\nEND", "The Food and Drug Administration (FDA) has given BioMarin Pharmaceutical\u00a0(NASDAQ: BMRN) a priority review for its valoctocogene roxaparvovec (valrox) gene therapy to treat patients with hemophilia A. The priority review will shave four months off of the review time for the marketing application, compared to a standard review. The agency expects to make a decision by Aug. 21, 2020.If approved, valrox would be the first gene therapy approved to treat hemophilia A. Currently, patients are treated with a protein called Factor VIII, which has to be infused two to three times per week and still doesn't prevent patients from all bleeding events. Valrox restores expression of Factor VIII in a patient's cells, eliminating the need for the replacement therapy.END", "Any way you look at it,\u00a0Invitae (NYSE: NVTA)\u00a0is smoking hot right now. The stock soared 46% last year and is up more than 60% so far in 2020.But Invitae's sizzle fizzled at least somewhat after the medical genetics company announced its fiscal 2019 fourth-quarter and full-year results following the market close on Wednesday. Here are the highlights from Invitae's Q4 update.END", "Genetic medicines and cellular therapies have an enormous potential to treat, and possibly cure, currently untreatable diseases. Nonetheless, it's important for investors to remember that \"simpler\" treatment options won't become obsolete just because gene therapy, gene editing, and immunotherapy approaches are becoming feasible.Investors are hoping that the 'simple is better' approach proves true for Codexis (NASDAQ: CDXS).\u00a0The company's first drug candidate, the enzyme-based CDX-6114, is being developed to treat a rare disease called phenylketonuria (PKU). Can the simpler approach of Codexis compete with a growing list of gene therapies that are also targeting the disease?END", "Investors in BioMarin Pharmaceutical Inc. (Symbol: BMRN) saw new options become available this week, for the March 20th expiration.   At Stock Options Channel, our YieldBoost formula has looked up and down the BMRN options chain for the new March 20th contracts and identified one put and one call contract of particular interest.The put contract at the $85.00 strike price has a current bid of $2.95.  If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $85.00, but will also collect the premium, putting the cost basis of the shares at $82.05 (before broker commissions).  To an investor already interested in purchasing shares of BMRN, that could represent an attractive alternative to paying $88.38/share today.\n\nBecause the $85.00 strike represents an approximate 4% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless.  The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 66%.  Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract.  Should the contract expire worthless, the premium would represent a 3.47% return on the cash commitment, or 21.86% annualized \u2014 at Stock Options Channel we call this the YieldBoost.\n\n\nBelow is a chart showing the trailing twelve month trading history for BioMarin Pharmaceutical Inc., and highlighting in green where the $85.00 strike is located relative to that history:\n\nEND", "Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. \tFor the First Trust NYSE Arca Biotechnology Index Fund ETF (Symbol: FBT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $181.90 per unit.\n\n\nWith FBT trading at a recent price near $152.05 per unit, that means that analysts see 19.63% upside for this ETF looking through to the average analyst targets of the underlying holdings.   Three of FBT's underlying holdings with notable upside to their analyst target prices are BioMarin Pharmaceutical Inc. (Symbol: BMRN), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Nektar Therapeutics (Symbol: NKTR). Although BMRN has traded at a recent price of $88.27/share, the average analyst target is 30.48% higher at $115.18/share. Similarly, ACAD has 26.99% upside from the recent share price of $43.43 if the average analyst target price of $55.15/share is reached, and analysts on average are expecting NKTR to reach a target price of $28.50/share, which is 26.78% above the recent price of $22.48. Below is a twelve month price history chart comparing the stock performance of BMRN, ACAD, and NKTR:  \n\n END", "Biotech stocks have proved to be an incredible wealth generator for long-term investors. In the prior decade, for instance, the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) nearly doubled the performance of the S&P 500. What's more, biotech equities may perform even better over the coming decade, thanks to the steady progress in key fields such as gene editing, gene therapy, and precision medicine. The biopharmaceutical industry, in fact, could make major strides over the next 10 years toward treating a range of diseases that currently have no standard of care.\u00a0Which biotech companies are set to lead the way in 2020? BioMarin Pharmaceutical (NASDAQ: BMRN),\u00a0CRISPR Therapeutics (NASDAQ: CRSP), and Novavax (NASDAQ: NVAX) are three top biotech stocks that might be worth owning this year. Here's a brief overview for each company.\u00a0END", "Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Glu Mobile Inc (Symbol: GLUU), where a total volume of 35,840 contracts has been traded thus far today, a contract volume which is representative of approximately 3.6 million underlying shares (given that every 1 contract represents 100 underlying shares).  That number works out to 64.9% of GLUU's average daily trading volume over the past month, of 5.5 million shares.  Especially high volume was seen for the $10 strike call option expiring March 20, 2020, with 7,408 contracts trading so far today, representing approximately 740,800 underlying shares of GLUU.  Below is a chart showing GLUU's trailing twelve month trading history, with the $10 strike highlighted in orange:\n\nEND", "Speaking at an interview at the J.P Morgan Healthcare Conference that's going on right now, BioMarin Pharmaceutical's (NASDAQ: BMRN) CEO Jean-Jacques Bienaim\u00e9 went on to say that the company was considering a hefty $2 million to $3 million dollar price tag for its hemophilia treatment, Valrox. If approved, the drug would be the first gene therapy in the U.S. that targets inherited hemophilia, one of the most common types of hemophilia out there. Clinical results have shown significant improvements in patients, with the number of bleeding incidents dropping to zero for years after receiving a Valrox injection.END", "After a stock takes a tumble, wait just a minute before you count it out. While falling share prices could be a sign that a company is under duress, it doesn\u2019t always mean that its growth story has come to an end. After all, a tried and true strategy to turn a profit in the market is to buy low and sell high.Wall Street pros remind investors to take this into consideration when gauging the strength of investments in the healthcare space. As these names rely on only a few key catalysts, all it takes is a single piece of bad news to send shares spiraling downwards. However, the opposite is also true, so one favorable outcome can put a stock right back on track.With this in mind, we used TipRanks\u2019 Stock Screener tool to pinpoint 3 Buy-rated healthcare names that the analysts believe are on the mend after recent nose dives. Here\u2019s the scoop straight from the analysts.BioMarin Pharmaceutical (BMRN) \u00a0\u00a0\u00a0BioMarin has established itself as a key player in the biopharma space, with seven therapies already on the market and several other candidates in development. Despite falling 21% in the first nine months of 2019, SunTrust Robinson analyst Robyn Karnauskas believes that important upcoming catalysts could drive a rebound.END", "(RTTNews) - Biomarin Pharmaceutical Inc. (BMRN) will participate in the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California.The event is scheduled to begin at 10:30 AM ET on January 13, 2020. To access the live webcast, log on to www.biomarin.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.END", "If you're interested in biotech stocks, you're not alone. The SPDR S&P Biotech ETF\u00a0has outperformed the S&P 500 in eight of the past 10 years, so the industry has been a great source of market-beating ideas.Biotech investing isn't easy, though. Clinical-trial failures, expiring patents, and stiff competition mean there's plenty of risk associated with owning biotech stocks. Nevertheless, the potential rewards associated with investing in the industry could make owning stocks with upcoming catalysts a great idea. For example,\u00a0BioMarin (NASDAQ: BMRN), Iovance Biotherapeutics (NASDAQ: IOVA), and Immunomedics (NASDAQ: IMMU)\u00a0have events coming up that could make buying shares this year smart.END", "Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in FibroGen Inc (Symbol: FGEN), where a total volume of 3,399 contracts has been traded thus far today, a contract volume which is representative of approximately 339,900 underlying shares (given that every 1 contract represents 100 underlying shares).  That number works out to 57.4% of FGEN's average daily trading volume over the past month, of 591,995 shares.  Especially high volume was seen for the $35 strike call option expiring January 17, 2020, with 3,015 contracts trading so far today, representing approximately 301,500 underlying shares of FGEN.  Below is a chart showing FGEN's trailing twelve month trading history, with the $35 strike highlighted in orange:\n\nEND", "2020 just kicked off, but investors aren\u2019t wasting any time. Rolling up their sleeves and getting straight down to business, they know the race is on to find the stocks ready to speed past the rest in the year ahead. To spot these investment opportunities, Wall Street pros recommend taking a step back and focusing on the bigger picture, telling investors to pay close attention to both upside potential and what the analyst community has to say.With this strategy in mind, what\u2019s the next step? For us, it was to take advantage of TipRanks\u2019 investing tools. The platform\u2019s Stock Screener tool let us filter our search results by analyst consensus, price target upside and Smart Score (TipRanks\u2019 numerical score made up of 8 metrics to measure the strength of an investment).As a result, we were able to pinpoint 3 stocks flagged by the Street\u2019s analysts as potential winners, with each boasting a \u201cStrong Buy\u201d consensus rating. Not to mention each has a top Smart Score, at least an 8 out of 10. Here\u2019s the scoop.BioMarin Pharmaceutical (BMRN)With seven products currently on the market as well as an impressive development pipeline, BioMarin has cemented its status as a biopharma heavyweight. While 2019 saw the company falter, this could be BMRN\u2019s year according to some members of the Street.END", "Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. \tFor the Biotech ETF (Symbol: BBH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $156.66 per unit.\n\n\nWith BBH trading at a recent price near $141.38 per unit, that means that analysts see 10.81% upside for this ETF looking through to the average analyst targets of the underlying holdings.   Three of BBH's underlying holdings with notable upside to their analyst target prices are Guardant Health Inc (Symbol: GH), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and IQVIA Holdings Inc (Symbol: IQV). Although GH has traded at a recent price of $81.24/share, the average analyst target is 42.54% higher at $115.80/share. Similarly, BMRN has 35.10% upside from the recent share price of $84.99 if the average analyst target price of $114.82/share is reached, and analysts on average are expecting IQV to reach a target price of $173.73/share, which is 16.06% above the recent price of $149.69. Below is a twelve month price history chart comparing the stock performance of GH, BMRN, and IQV:  \n\n END", "Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in DocuSign Inc (Symbol: DOCU), where a total volume of 11,830 contracts has been traded thus far today, a contract volume which is representative of approximately 1.2 million underlying shares (given that every 1 contract represents 100 underlying shares).  That number works out to 75.6% of DOCU's average daily trading volume over the past month, of 1.6 million shares.  Particularly high volume was seen for the $65 strike call option expiring January 17, 2020, with 7,507 contracts trading so far today, representing approximately 750,700 underlying shares of DOCU.  Below is a chart showing DOCU's trailing twelve month trading history, with the $65 strike highlighted in orange:\n\nEND", "(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN) reported positive final results from its double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of vosoritide in Children with achondroplasia. In the study, placebo-adjusted increase in growth velocity was 1.6 cm/yr. Vosoritide was generally well tolerated. Based on the results, the company plans to meet with health authorities in the first half of 2020 to discuss plans for submitting marketing applications. \"The placebo-controlled study demonstrated a strong increase in growth velocity across the broad population studied. These results when combined with the long-term benefits seen in the phase 2 study provide hope for a significant and sustained benefit for children with achondroplasia,\" said Hank Fuchs, President Worldwide Research and Development at BioMarin.Shares of BioMarin Pharma were up 7% in pre-market trade on Monday. END", "(RTTNews) - 2019 saw more than 25 acquisition deals being executed in the biotech sector, of which 14 were billion-dollar deals. Bristol-Myers Squibb (BMY) acquiring Celgene for $74 billion in January remains the most expensive acquisition of this year.In the wake of generic drugs eating into the sales of off-patent branded drugs,  growing pressure from regulators to reduce the prices of drugs, drying pipelines, and ever-increasing R&D costs, there has been an increasing consolidation within the drug industry. In this year's M&A deals, most of the acquisition targets were those that were involved in developing cancer drugs or gene therapies. Let's take a look at some of the biotech companies that have been in the acquisition crosshairs for quite some time.END", "Alnylam (ALNY) is a U.S.-based biopharma company primarily developing RNA interference drugs.\u00c2\u00a0The company recently announced that the USFDA has approved its drug Givlaari, which has proven effective in silencing the gene behind the rare metabolic disease acute hepatic porphyrias.\u00c2\u00a0This drug was approved 3 months ahead of schedule and only 16 months after the drug was first filed, boosting the outlook for the firm\u2019s revenues and profits. Notably, the company currently only has one commercial drug in the market \u2013 Onpattro. Givlaari will soon be the second one.\u00c2\u00a0The company\u2019s improved prospects after Givlaari\u2019s approval drove the rally in Alnylam\u2019s stock.We step back from these recent swings to review Alnylam\u00e2\u0080\u0099s\u00c2\u00a0performance over the last few years, as a context for what might come next. Our Interactive dashboard \u2013 Exploring The Reason Behind The 25% Jump in Alnylam\u00e2\u0080\u0099s Stock In A Fortnight,\u00c2\u00a0reviews the near term reasons and the big picture.The context for the last few years:A closer look At Alnylam\u00e2\u0080\u0099s\u00c2\u00a0Total Revenues over the last few years and the outlook.Total Revenues for Alnylam substantially decreased from $89.9 Mil in 2017 to $74.9 Mil in 2018; a decline by 16.7%. (On account of lower R&D collaboration revenue)END", "Alnylam (ALNY) is a U.S.-based biopharma company primarily developing RNA interference drugs.\u00a0The company recently announced that the USFDA has approved its drug Givlaari, which has proven effective in silencing the gene behind the rare metabolic disease acute hepatic porphyrias.\u00a0This drug was approved 3 months ahead of schedule and only 16 months after the drug was first filed, boosting the outlook for the firm\u2019s revenues and profits. Notably, the company currently only has one commercial drug in the market \u2013 Onpattro. Givlaari will soon be the second one.\u00a0The company\u2019s improved prospects after Givlaari\u2019s approval drove the rally in Alnylam\u2019s stock.We step back from these recent swings to review Alnylam\u2019s\u00a0performance over the last few years, as a context for what might come next. Our Interactive dashboard \u2013 Exploring The Reason Behind The 25% Jump in Alnylam\u2019s Stock In A Fortnight,\u00a0reviews the near term reasons and the big picture.The context for the last few years:A closer look At Alnylam\u2019s\u00a0Total Revenues over the last few years and the outlook.Total Revenues for Alnylam substantially decreased from $89.9 Mil in 2017 to $74.9 Mil in 2018; a decline by 16.7%. (On account of lower R&D collaboration revenue)END", "Alnylam (ALNY) is a U.S.-based biopharma company primarily developing RNA interference drugs.\u00c2\u00a0The company recently announced that the USFDA has approved its drug Givlaari, which has proven effective in silencing the gene behind the rare metabolic disease acute hepatic porphyrias.\u00c2\u00a0This drug was approved 3 months ahead of schedule and only 16 months after the drug was first filed, boosting the outlook for the firm\u2019s revenues and profits. Notably, the company currently only has one commercial drug in the market \u2013 Onpattro. Givlaari will soon be the second one.\u00c2\u00a0The company\u2019s improved prospects after Givlaari\u2019s approval drove the rally in Alnylam\u2019s stock.We step back from these recent swings to review Alnylam\u00e2\u0080\u0099s\u00c2\u00a0performance over the last few years, as a context for what might come next. Our Interactive dashboard \u2013 Exploring The Reason Behind The 25% Jump in Alnylam\u00e2\u0080\u0099s Stock In A Fortnight,\u00c2\u00a0reviews the near term reasons and the big picture.The context for the last few years:A closer look At Alnylam\u00e2\u0080\u0099s\u00c2\u00a0Total Revenues over the last few years and the outlook.Total Revenues for Alnylam substantially decreased from $89.9 Mil in 2017 to $74.9 Mil in 2018; a decline by 16.7%. (On account of lower R&D collaboration revenue)END", "END", "Gene editing holds tremendous promise to help patients and potentially cure a multitude of inherited diseases. Editas Medicine (NASDAQ: EDIT) and Sangamo Therapeutics (NASDAQ: SGMO) employ technologies aimed at removing, replacing, or editing sections of the human genome.Editas focuses on a relatively recent technology called CRISPR while Sangamo uses several technologies including what is called zinc finger technology. Both approaches allow for precise gene editing by breaking the DNA strand and either inserting new DNA sequences or deleting sections of damaged or mutated DNA.END", "(RTTNews) - Today's Daily Dose brings you news about Akero's NASH study update; Axsome Therapeutics' major depressive disorder trial results; CEL-SCI's near-term catalyst; BioMarin's promising results of achondroplasia drug candidate; Wave Life Sciences decision to discontinue the development of DMD drug candidate and more.Read on\u2026Akero Therapeutics Inc. (AKRO) has completed enrollment in its phase IIa study of AKR-001 in non-alcoholic steatohepatitis, dubbed BALANCED.The study randomized 80 participants to receive weekly subcutaneous doses of AKR-001 or placebo for up to 16 weeks, with safety and tolerability followed through week 20. Topline results from the BALANCED study are expected in the first quarter of 2020, with full data readout anticipated in the second quarter of 2020.AKRO closed Monday's trading at $19.45, down 7.78%.END", "Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. \tFor the First Trust NASDAQ-100 Ex-Technology Sector Index Fund ETF (Symbol: QQXT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $61.85 per unit.\n\n\nWith QQXT trading at a recent price near $56.10 per unit, that means that analysts see 10.25% upside for this ETF looking through to the average analyst targets of the underlying holdings.   Three of QQXT's underlying holdings with notable upside to their analyst target prices are BioMarin Pharmaceutical Inc. (Symbol: BMRN), T-Mobile US Inc (Symbol: TMUS), and Booking Holdings Inc (Symbol: BKNG). Although BMRN has traded at a recent price of $75.04/share, the average analyst target is 50.81% higher at $113.17/share. Similarly, TMUS has 15.23% upside from the recent share price of $78.07 if the average analyst target price of $89.96/share is reached, and analysts on average are expecting BKNG to reach a target price of $2079.47/share, which is 12.48% above the recent price of $1848.82. Below is a twelve month price history chart comparing the stock performance of BMRN, TMUS, and BKNG:  \n\n END"]}